Servier Announces FDA Approval of TIBSOVO(R) (ivosidenib table...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
BOSTON, May 26, 2022 /PRNewswire-AsiaNet/-- --TIBSOVO is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia--FDA approval based on data from the global, Phase 3 AGILE trial that dem...
Authors: LATEST ASIANET NEWS RELEASES